Introduction
The incidence of pneumococci resistant to penicillin G and other -lactams and non--lactams has increased worldwide at an alarming rate, including in the USA. 1 In the USA there has been an increase in resistance to penicillin from Ͻ5% before 1989 (including Ͻ0.02% of isolates with MICs у 2.0 mg/L) to 6.6% in 1991-1992 (with 1.3% of isolates with MICs у 2.0 mg/L) and to 23.6% of 1527 strains during 1994-1995. 2 Oral compounds for the out-patient treatment of respiratory tract infections caused by penicillin-intermediate and -resistant pneumococci are urgently required. 3, 4 Older quinolones such as ciprofloxacin and ofloxacin exhibit moderate in vitro activity against pneumococci, with MICs clustering around breakpoints. 4 Methods for routine susceptibility testing of pneumococci include broth microdilution and disc diffusion (recommended by the National Committee for Clinical Laboratory Standards) (NCCLS), agar dilution and Etest.
5-7 NCCLS recommends incubation of microdilution MICs in air, but disc diffusion in CO 2 , 5,6 while the manufacturer of the Etest recommends incubation in CO 2 . 7 There are no standard recommendations for agar dilution pneumococcal MIC testing methodology, although agar dilution has been extensively used in this laboratory. 4, 7 If new compounds are to be tested for antipneumococcal activity in the clinical laboratory, methodology must be standardized. This study used microdilution and agar dilution (in air), Etest (in air and CO 2 ) and disc diffusion (in air and CO 2 ) to test the activity of gemifloxacin (SB 265805; LB 20304a), a new fluoronaphthyridone with a novel pyrrolidone substituent, with good Gram-positive and -negative activity, [8] [9] [10] against 200 pneumococci. 
Materials and methods

Bacteria and antibiotics
Microdilution MICs
These were determined by the NCCLS method, 5 using cation-adjusted Mueller-Hinton broth (Difco) with 5% lysed defibrinated horse blood. Trays were prepared inhouse. Suspensions with a turbidity equivalent to that of a 0.5 McFarland standard were prepared by suspending growth from blood agar plates in 2 mL Mueller-Hinton broth, and further diluted 1:10 to obtain a final inoculum (10 L) containing 5 ϫ 10 5 cfu/mL. Trays were incubated for 20-24 h in ambient air at 35°C. Standard quality control strains (as above) were included in each run.
Etest MICs
Standard methodology was used. 7 Mueller-Hinton plates supplemented with 5% sheep blood (BBL Microbiology Systems, Cockeysville, MD, USA) were inoculated with a 0.5 McFarland suspension harvested from plates, and Etest strips placed on each. After overnight incubation at 35°C, the MIC was read as the intersect where the ellipse of growth inhibition intersects the strip. Etest MICs were performed both in air and in CO 2 . Etest MICs were rounded up to the next highest doubling dilution.
Disc diffusion
This was by standard NCCLS methodology 6 using 5 g gemifloxacin discs (BBL) and Mueller-Hinton plates supplemented with 5% sheep blood (BBL), inoculated with a 0.5 McFarland suspension. After overnight incubation in both air and 5% CO 2 at 35°C, zone diameters were measured with calipers.
Results
By agar dilution, ciprofloxacin MICs (mg/L) for all strains ranged between 0.5 and у64, with an MIC 50 of 2 mg/L and an MIC 90 of 16 mg/L (Table I) (Table I) . Results of agar dilution MICs for ciprofloxacin and gemifloxacin for all 200 strains tested showed a linear correlation.
Agreements of microdilution and Etest (air and CO 2 ) with agar dilution (used as the reference method) and Etests in air compared with CO 2 are presented in Table II . As can be seen, 187/200 strains (93.5%) gave essential agreement (± 1 log 2 dilution) with microdilution, and 98.0% with the Etest (both in air and CO 2 ). With a preliminary breakpoint of 0.5 mg/L, no major or very major discrepancies were found with microdilution in air or Etest in air or CO 2 . Etests incubated in air gave virtually identical results to those in CO 2 (Table II) .
With discs incubated in CO 2 , all quinolone-susceptible strains yielded zone diameters у26 mm; values in air were у28 mm. Zone diameters for quinolone-resistant strains in CO 2 varied between 18 and 31 mm but were mostly 21-26 mm; zone diameters in air were a few millimetres wider, but were also mostly Ͻ31 mm. Using a gemifloxacin breakpoint of 0.5 mg/L, у20 mm for susceptible and р19 mm (resistant) are proposed. All strains but one (with agar dilution) had MICs of р0.5 mg/L and all but one strain yielded zones of Ͼ20 mm. With a breakpoint of 0.25 mg/L, 
Discussion
MICs of gemifloxacin for pneumococci are similar to those 7 Disc diffusion showed zone sizes slightly smaller in CO 2 than in air. Determination of breakpoints, both by disc diffusion and MIC, must await further studies, but ciprofloxacin-resistant strains with gemifloxacin MICs of 0.06-1.0 mg/L by agar dilution, gave zone diameters in CO 2 between 21 and 31 mm (with the exception of one strain with a zone diameter of 18 mm), and most quinolonesusceptible strains yielded zone diameters Ͼ 25 mm.
Agar or microdilution MICs were not determined in CO 2 . NCCLS recommends incubation in air for microdilution and suggests (but does not recommend) incubation in air for agar dilution, in contrast to CO 2 for disc diffusion, and Etest incubation in CO 2 being recommended by the manufacturer. This is clearly not optimal, and there is a need for standardization of pneumococcal susceptibility testing, with all methods in CO 2 . However, a previous study has shown a negligible effect of CO 2 on pneumococcal susceptibility testing with another quinolone, levofloxacin. 7 Our results indicate an excellent correlation between agar dilution, microdilution and Etest, and all methods can confidently be recommended for pneumococcal susceptibility testing with gemifloxacin. Using a gemifloxacin breakpoint of 0.5 mg/L, у20 mm for susceptible and р19 mm are proposed (see Results). With a breakpoint of 0.25 mg/L, zone diameters (mm) of у23 (susceptible), 21-22 (intermediate) and р20 (resistant) are suggested. 
